Epidermal Growth Factor Receptor (EGFR) Mutation Does Not Correlate with Platinum Resistance in Ovarian Carcinoma. Results of a Prospective Pilot Study

• Published in: Anticancer research Vol. 27; no. 3B; pp. 1527 - 1530
• Main Authors: MUSTEA, Alexander, SEHOULI, Jalid, FABJANI, Gerhild, KOENSGEN, Dominique, MÖBUS, V, BRAICU, Elena Ioana, PIRVULESCU, Cristina, THOMAS, Anke, DAN TONG, ZEILLINGER, Robert
• Format: Journal Article
• Language: English
• Published: Attiki International Institute of Anticancer Research 01-05-2007
• Subjects: Adult; Aged; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Carcinoma - drug therapy; Carcinoma - mortality; Carcinoma - surgery; DNA Mutational Analysis; Drug Resistance, Neoplasm - genetics; Female; Female genital diseases; Gynecology. Andrology. Obstetrics; Humans; Medical sciences; Middle Aged; Mutation, Missense; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - mortality; Ovarian Neoplasms - surgery; Pilot Projects; Platinum Compounds - therapeutic use; Prospective Studies; Receptor, Epidermal Growth Factor - genetics; Sequence Deletion; Survival; Tumors; Ovary carcinoma; ovarian cancer; Ovary cancer; pyrosequencing; Malignant tumor; Epidermal growth factor receptor; EGFR; Female genital diseases; Prospective; Resistance; Ovarian diseases; Growth factor receptor; Cancerology; Platinum; Genetics; Mutation
• ISSN: 0250-7005; 1791-7530

Background: Different studies have demonstrated epidermal growth factor receptor (EGFR) status as an independent prognostic
factor for ovarian cancer (OC). Recent studies in non-small cell lung cancer suggest that the presence of a clinical response
to tyrosine kinase inhibitors correlates with somatic mutations in the kinase domain of EGFR, exons 18-21. For patients with
OC, data are not available on EGFR gene mutation. Materials and Methods: Shock-frozen samples from 32 patients with OC were
screened for L858R deletion mutations of EGFR within exon 21 of the kinase domain and 15 bp deletion in exon 19. Additionally,
nine commercially available OC cell lines and 32 established OC lines were analysed. Results: In cell lines, as well as in
tumor samples, stratified to platinum-free therapy interval, no mutation of the EGFR gene was observed. Conclusion: Mutations
in the kinase domain of the EGFR, exons 19 and 21, are absent or very infrequent in patients with OC.